Cell Type: hybridoma: B lymphocyte; somatic cell hybrid
Permits/Forms:
In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Comments:
Animals were immunized with purified bacterially expressed fusion proteins containing BRCA1 amino acids 1360 to 1555. Spleen cells were fused with the mouse myeloma cell line P3.653. Monoclonal antibodies BR1H-788.6 (ATCC PTA-4301), BR1H-945.2 (ATCC PTA-4303) and BR1H-826.5 (ATCC PTA-4302) are against a portion of a BRCA1 polypeptide between the N-terminal and C-terminal regions of the BRCA1 polypeptide (amino acids 1360 to 1555).Monoclonal antibodies BR1N.129.5 (ATCC PTA-4304) and BR1N-411.4 (ATCC PTA-4305) are against the N-terminal region of a BRCA1 polypeptide (amino acids 1 to 304).Monoclonal antibodies BR1S-218.1 (ATCC PTA-4307), BR1S-060.2 (ATCC PTA-4306), BR1S-384.5 (ATCC PTA-4308), and BR1S-425.1 (ATCC PTA-4309) are against the C-terminal region of a full-length BRCA1 polypeptide (amino acids 1840-1862). These antibodies can be used to detect BRCA1 mutations.
68856: Li H, et al. A novel tricomplex of BRCA1, Nmi, and c-Myc inhibits c-Myc-induced human telomerase reverse transcriptase gene (hTERT) promoter activity in breast cancer. J. Biol. Chem. 277: 20965-20973, 2002. PubMed: 11916966 89590: Knott CL, Kuus-Reichel K. Methods of detecting BRCA1 mutations. U.S. Patent 6,514,713 dated Feb 4 2003 89663: Kumar A, et al. BRCA1 partially reverses the transforming activity of the ras oncogene. Neoplasma 1: 417-423, 1999. PubMed: 10933056